EPA/EPO/OEB
D-80298 München
+49 89 2399-0
TX 523 656 epmu d
FAX +49 89 2399-4465

Europäisches Patentamt | European Patent Office | Office européen des brevets

Generaldirektion 2 | Directorate General 2 | Direction Générale 2

1 OCT 1999

Jump, Timothy John Simon
Venner Shipley & Co.
20 Little Britain
London EC1A 7DH
GRANDE BRETAGNE

Application No.	Ref.	Date
92 922 300.6-2110	TSJ/BD/31907	29.09.99

Applicant
NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. et al.

Communication under Rule 51(4) EPC

You are hereby informed that the Examining Division intends to grant a European patent on the basis of the above application with the text and drawings as indicated below:

Text for the Contracting States:
AT BE CH LI DE DK ES FR GB GR IE IT NL SE

Description, pages:

7-10,13,15,16	as originally filed			
1,11,12,14,17, 18	as received on	03.11.1997	with letter of	31.10.1997
2-6	as received on	14.06.1999	with letter of	11.06.1999

Claims, No.:

1-12	as received on	14.06.1999	with letter of	11.06.1999

Drawings, sheets:

With the following amendments to the above-mentioned documents by the division.

Description, page: 1

Comments.

1. The relevant prior art has been introduced on page 1 (Rule 27(1)(b) EPC.

A copy of the relevant documents is enclosed.

The title of the invention in the three official languages of the European Patent Office, the international patent classification, the designated Contracting States and the registered name of the applicant are shown on the attached EPO Form 2056.

You are requested to state your approval of the text specified above **within four months** of this notification. Failure to do so will result in refusal of the application under Article 97(1) EPC, except as provided by Rule 51(5) EPC, second sentence.

The filing of a divisional application is only possible up to the approval of the text specified above (Rule 25(1) EPC). Concerning the possibility of a request for accelerated grant pursuant to Article 97(6) EPC, reference is made to OJ EPO 1995, 841.

Further information concerning the acceptability of amendments or the filing of a separate set of claims for one or more designated Contracting States that have entered a reservation under Article 167(2)a) EPC will be found in the Guidelines for Examination in the EPO, C-VI, 4.8 - 4.10 and C-VI, 15.1.2 - 15.1.4.

If the translation of the priority document(s), as required by Article 88(1) EPC, or the declaration according to Rule 38(4) EPC has not yet been filed, it is to be filed within the time limit mentioned in Rule 38(4) EPC at the latest.

Examining Division:

Chairman:	MOONEN P
2nd Examiner:	DEFFNER C A E
1st Examiner:	DOEPFER K

EUROPÄISCHES PATENTAMT · EUROPEAN PATENT OFFICE · OFFICE EUROPÉEN DES BREVETS

DA ROCHA, O.
For the Examining Division

Enclosure(s): 1 sheet(s) 2056
1 Copies of the relevant documents

EPA/EPO/OEB
D-80298 München
+49 89 2399-0
TX 523 656 epmu d
FAX +49 89 2399-4465

Europäisches Patentamt | European Patent Office | Office européen des brevets

Generaldirektion 2 | Directorate General 2 | Direction Générale 2

Jump, Timothy John Simon
Venner Shipley & Co.
20 Little Britain
London EC1A 7DH
GRANDE BRETAGNE

Application No.	Ref.	Date
92 922 300.6-2110	TSJ/BD/31907	29.09.99

Applicant
NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. et al.

For the intended grant of a European patent, (1) the title of the invention in the three official languages of the European Patent Office, (2) the International Patent Classification, (3) the designated Contracting States and (4) the applicant's registered name, address and country of residence or principal place of business are set out below.

(1)
- INHIBITOREN DER DIPEPTIDYL-AMINOPEPTIDASE VOM TYP-IV
- INHIBITORS OF DIPEPTIDYL-AMINOPEPTIDASE TYPE IV
- INHIBITEURS DE DIPEPTIDYL-AMINOPEPTIDASE DE TYPE IV

(2) C07K5/06, C07K5/10, C07K7/06, C07K7/08, C07F5/02, A61K31/69, A61K38/04

(3) AT BE CH LI DE DK ES FR GB GR IE IT NL SE

(4) NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.
750 Washington Street, Box 817
Boston
Massachusetts 02111
US

TUFTS UNIVERSITY
Packard Hall
Medford,
MA 02155
US

INHIBITORS OF DIPEPTIDYL-AMINOPEPTIDASE TYPE IV

This invention relates to inhibitors of the amino peptidase activity of dipeptidyl peptidase type IV (DP-IV).

DP-IV is a postproline cleaving enzyme with a specificity for removing Xaa-Pro (where Xaa represents any amino acid) dipeptides from the amino terminus of polypeptides. DP-IV will also remove Xaa-Ala dipeptides from amino termini, albeit less efficiently. DP-IV is present in many mammalian cells and tissues, for example, renal tubule cells, intestinal epithelium, and blood plasma. It is also present on the surface of CD4+ and some CD8+ T-cells. It is thought to be involved in the regulation of the immune response; occurrence of DP-IV on a cell surface is associated with the ability of cells to produce interleukin-2 (IL-2). DP-IV is also referred to as dipeptidyl-peptide hydrolase DAP-IV or DPP-IV; it is assigned EC number 3.4.14.5.

Three different inhibitors of DP-IV are known. One of these is a suicide inhibitor: N-Ala-Pro-O-(nitrobenzyl-) hydroxylamine. (The standard three letter amino acid codes are used in this application; O represents oxygen.) Another is a competitive inhibitor: e-(4-nitro) benzoxycarbonyl-Lys-Pro. The third is a polyclonal rabbit anti-porcine kidney DP-IV immunoglobulin.

< >

The enzymatic activity of DP-IV involves cleaving of a dipeptide from the free amino terminus of a polypeptide. DP-IV has a preference for cleaving after [illegible] amino terminus. A free amino terminus is required; thus, DP-IV is a postproline cleaving enzyme with a

< Peptides containing [illegible] are known as inhibitors of DP-IV [illegible] et al. Biochemistry 27: 7682-7688 (1988) > and of inhibitors in general

specificity for removing an N-terminal Xaa-Pro dipeptide from a polypeptide (where Xaa can be any amino acid, including proline). DP-IV also will remove a Xaa'-Ala dipeptide from an amino terminus of a polypeptide when Xaa' is an amino acid with a bulky side group, e.g., tyrosine.

This invention concerns provision of potent inhibitors of the enzymatic activity of DP-IV. Generally, an α-amino boronic acid analog of proline (boroPro is used to designate one such analog which has the carboxyl group of proline replaced with a $B(OH)_2$ group, where $(OH)_2$ represents two hydroxyl groups and B represents boron) is bonded to an amino acid to form a dipeptide with boroPro as the carboxy terminal residue. These dipeptide prolyl-boronic acids are potent and highly specific inhibitors of DP-IV, with K_i values in the nanomolar range.

Dipeptides having the boroPro moiety are relatively unstable; thus, as one possibility, we have designed inhibitors having at least two other amino acid residues. Generally, the structure of these inhibitors is X-Pro-Y-boroPro where X and Y are chosen from any amino acid residue (including proline). This tetrapeptide may be lengthened at its amino-terminus by addition of one or more dipeptides, each dipeptide having the general formula Z-Pro or Z-ala, where each Z independently is any amino acid residue (including proline). This general structure is defined in more detail below. These inhibitors function as inhibitors of DP-IV because each dipeptide portion is a substrate for DP-IV and the final product of the reaction of such an inhibitor with DP-IV is the dipeptide inhibitor Y-boroPro. The amino terminus of these inhibitors must not be blocked or they lose their inhibitory capacity for DP-IV since DP-IV cannot

In accordance with a first aspect of the invention, a purified inhibitor of the amino peptidase activity of dipeptidyl peptidase type IV (DP-IV) is provided, having the structure:



wherein m is an integer between 0 and 10, inclusive; A and A′ are L-amino acid residues (for glycine there is no such distinction) such that the A in each repeating bracketed unit can be a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A′ and C, and between A′ and N are peptide bonds; and each X^1 and X^2 is, independently, a hydroxyl group or a group capable of being hydrolysed to a hydroxyl group at physiological pH. By "the C bonded to B is in the L-configuration" is meant that the absolute configuration of the C is like that of an L-amino acid.

Thus the  group has the same relationship to the C as the -COOH group of an L-amino acid has to its α carbon. In various preferred embodiments, A and A′ are independently proline or alanine residues; m is 0; X^1 and

Preferably, X^1 and X^2 from the general formula are hydroxyl groups.

In a further preferred embodiment, A and A' are independently proline or alanine residues.

In an inhibitor according to the present invention wherein m is 0, A' is desirably other than alanine.

One example of a preferred inhibitor according to the present invention is L-Ala-L-boroPro.

Another example of a preferred inhibitor according to the present invention is L-Pro-L-boroPro.

An inhibitor according desirably has an isomeric purity of about 96-99%.

According to a preferred embodiment, an inhibitor according to the first aspect of the invention is for use in inhibiting the enzymatic activity of DP-IV in a mammal, preferably for regulation of an immune response.

To that end, according to a second aspect of the invention, a pharmaceutical composition is provided comprising one or more inhibitors according to the first aspect of the invention, together with a pharmaceutical carrier or diluent.

According to a third aspect of the invention, a preparation is provided comprising an inhibitor according to the first aspect of the invention, or a composition according to the second aspect, wherein said inhibitor is present with an isomeric purity of about 96-99%.

A fourth aspect of the present invention provides the use of an inhibitor according to the first aspect of the invention, for the manufacture of a medicament for use in inhibiting the enzymatic activity of DP-IV in a mammal, preferably for regulation of an immune response.

[illegible] agent is suitable

[illegible] the mammal per day.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments, and from the claims.

Description of the Preferred Embodiments

The drawing will first be briefly described.

Drawing

Fig. 1 is a diagrammatic representation of the synthesis of a boro proline compound.

Structure

The inhibitory compounds of the invention have the general structure recited in the Summary of the Invention above. Examples of preferred structures are those referred to as preferred embodiments above.

The structure of the preferred inhibitory compounds is such that at least a portion of the amino acid sequence near the cleavage site of a DP-IV substrate is duplicated, or nearly duplicated. This duplication is in part responsible for the ability of the inhibitory compounds to inhibit DP-IV, by a mechanism thought to involve competitive inhibition between a DP-IV inhibitory compound or a DP-IV cleavage product of the inhibitory compound, and the actual DP-IV substrate.

The choice of amino acid sequence affects the inhibitory activity of the inhibitory compound, and its specificity. Peptide fragments can be synthesized and then tested to determine their efficacy as inhibitors, using standard techniques. Specificity is determined in a similar fashion, by testing the inhibitory effect of a particular inhibitory compound on the enzyme activity. The inhibitory compounds preferably inhibit the enzymatic

[illegible] inhibit enzymes necessary

The inhibitory compounds include the group:



which causes the inhibitory compound to complex with DP-IV, not only in a competitive fashion, but in a chemically reactive manner to form a strong bond between the inhibitory compound and DP-IV. This group thus acts to bind the inhibitory compound to DP-IV, and increases the inhibitory binding constant (K_i) of the inhibitory compound.

Synthesis of BoroProline

Referring to Fig. 1, the starting compound I is prepared essentially by the procedure of Matteson et al. (*Organometallics* 3:1284, 1984), except that a pinacol ester is substituted for the pinanediol ester. Similar compounds such as boropipecolic acid and 2-azetodine boronic acid can be prepared by making the appropriate selection of starting material to yield the pentyl and propyl analogs of compound I. Further, Cl can be substituted for Br in the formula, and other diol protecting groups can be substituted for pinacol in the formula, e.g., 2, 3-butanediol and alpha-pinanediol.

Compound II is prepared by reacting compound I with $[(CH_3)O_3Si]_2N$-Li+. In this reaction hexamethyldisilazane is dissolved in tetrahydrofuran and an equivalent of n-butyllithium added at -78°C. After warming to room temperature (20°C) and cooling to -78°C, [illegible] equivalent of compound I is added in tetrahydrofuran. [illegible] were [illegible] come [illegible] temperature and to stir overnight. The alpha-bis(trimethylsilane)-protected amine is isolated by evaporating solvent and adding hexane under anhydrous conditions. Insoluble

→ p. 10

residue is removed by filtration under a nitrogen blanket, yielding a hexane solution of compound II.

Compound III, the N-trimethysilyl protected form of boroProline is obtained by the thermal cyclization of compound II during the distillation process in which compound II is heated to 100-150° and distillate is collected which boils 66-62°C at 0.06-0.10 mm pressure.

Compound IV, boroProline-pinacol hydrogen chloride, is obtained by treatment of compound III with HCl:dioxane. Excess HCl and by-products are removed by trituration with ether. The final product is obtained in a high degree of purity by recrystallization from ethyl acetate.

The boroProline esters can also be obtained by treatment of the reaction mixture obtained in the preparation of compound II with anhydrous acid to yield 1-amino-4-bromobutyl boronate pinacol as a salt. Cyclization occurs after neutralizing the salt with base and heating the reaction.

Preparation of boroProline-pinacol

The intermediate, 4-Bromo-1-chlorobutyl boronate pinacol, was prepared by the method in Matteson et al. (*Organometallics* 3:1284, 1984) except that conditions were modified for large scale preparations and pinacol was substituted for the pinanediol protecting group.

3-bromopropyl boronate pinacol was prepared by hydrogenboronation of allyl bromide (173 ml, 2.00 moles) with catechol borane (240 ml, 2.00 moles). Catechol borane was added to allyl bromide and the reaction heated for 4 hours at 100°C under a nitrogen atmosphere. The

[illegible] catechol (bp 95-102°C

[illegible] catechol ester (124 g, [illegible].52 moles) was transesterified with pinacol (61.5 g, 0.52 moles) by mixing the component in 50 ml of THF and allowing them to

stir for 0.5 hours at 0°C and 0.5 hours at room temperature. Solvent was removed by evaporation and 250 ml of hexane added. Catechol was removed as a crystalline solid. Quantitative removal was achieved by successive dilution to 500 ml and to 1000 ml with hexane and removing crystals at each dilution. Hexane was evaporated and the product distilled to yield 177 g (bp 60 - 64°C, 0.35 mm).

4-Bromo-1-chlorobutyl boronate pinacol was prepared by homologation of the corresponding propyl boronate. Methylene chloride (50.54 ml, 0.713 moles) was dissolved in 500 ml of THF, 1.54 N n-butyllithium in hexane (480 ml, 0.780 moles) was slowly added at -100°C. 3-Bromopropyl boronate pinacol (178 g, 0.713 moles) was dissolved in 500 ml of THG, cooled to the freezing point of the solution, and added to the reaction mixture. Zinc chloride (54.4 g, 0.392 moles) was dissolved in 250 ml of THG, cooled to 0°C, and added to the reaction mixture in several portions. The reaction was allowed to slowly warm to room temperature and to stir overnight. Solvent was evaporated and the residue dissolved in hexane (1 liter) and washed with water (1 liter). Insoluble material was discarded. After drying over anhydrous magnesium sulfate and filtering, solvent was evaporated. The product was distilled to yield 147 g (bp 110 - 112°C, 0.200 mm).

N-Trimethylsilyl-boroProline pinacol was prepared first by dissolving hexamethyldisilizane (20.0 g, 80.0 mmoles) in 30 ml of THF, cooling the solution to -78°C, and adding 1.62 N n-butyllithium in hexane (49.4 ml, 80.0

[illegible] chlorobutyl boronate pinacol (23.9 g, 80.0 mmoles) added in 20 ml of THF. The mixture was allowed to slowly warm to room temperature and to stir overnight. Solvent was

hindered base) are added to a solution of H-boroPro-pinacol dissolved in either cold chloroform of tetrahydrofuran.

The reaction mixture is routinely stirred for one hour at -20°C and 1 to 2 hours at room temperature (20°C). Solvent is removed by evaporation, and the residue is dissolved in ethyl acetate. The organic solution is washed with 0.20N hydrochloric acid, 5% aqueous sodium bicarbonate, and saturated aqueous sodium chloride. The organic phase is dried over anhydrous sodium sulfate, filtered, and evaporated. Products are purified by either silica gel chromatography or gel permeation chromatography using Sephadex™ LH-20 and methanol as a solvent.

Previous studies have shown that the pinacol protecting group can be removed *in situ* by preincubation in phosphate buffer prior to running biological experiments (Kettner et al., *J. Biol. Chem.* 259:15106, 1984). Several other methods are also applicable for removing pinacol groups from peptides, including boroProline, and characterizing the final product. First, the peptide can be treated with diethanolamine to yield the corresponding diethanolamine boronic acid ester, which can be readily hydrolyzed by treatment with aqueous acid or a sulfonic acid substituted polystyrene resin as described in Kettner et al. (*supra*). Both pinacol and pinanediol protecting groups can be removed by treating with BC13 in methylene chloride as described by Kinder et al. (*J. Med. Chem.* 28:1917). Finally, the free boronic acid can be converted to the difluoroboron

Similarly, different ester groups can be introduced by reacting the free boronic acid with various

di-hydroxy compounds (for example, those containing heteroatoms such as S or N) in an inert solvent.

Preparation of H-Ala-boroPro

Boc-Ala-boroPro was prepared by mixed anhydride coupling of the N-Boc-protected alanine and H-boroPro prepared as described above. H-Ala-boroPro (Ala-boroPro) was prepared by removal of the Boc protecting group at 0°C in 3.5 molar excess of 4N HCl-dioxane. The coupling and deblocking reactions were performed by standard chemical reaction. Ala-boroPro has a K_i for DP-IV of in the nanomolar range. Boc-blocked Ala-boroPro has no affinity for DP-IV.

One significant drawback with H-Ala-boroPro as an inhibitor for DP-IV is that is decomposes in aqueous solution at neutral pH and room temperature (20 - 25°C) with a half-life of around 0.5 hour. Many dipeptide derivatives with a free N terminal amino group and a functional group (such as a difluoromethyl ketone) on the C-terminus are similarly unstable due to intramolecular reaction. A six member ring is formed between the amino and C-terminal functional groups and undergoes subsequent further reaction, such as hydrolysis. DP-IV bound inhibitor is more stable, consistent with the hypothesis that decomposition is due to an intramolecular reaction.

H-Pro-boroPro is more stable than H-Ala-boroPro. The K_i of H-Pro-boroPro for DP-IV is about 1×10^{-8}M, and it decomposes in aqueous solution at room temperature (20-25°C) with a half life of about 1.5 hours. Although the affinity of H-Pro-boroPro is about 10-fold less than that of H-Ala-boroPro, the increased stability is

Because of the relatively short half life of the above dipeptides our inhibitory compounds are formed as tetrapeptides or longer peptides in one aspect of the invention. These inhibitory compounds

are substrates for DP-IV yielding the dipeptide inhibitor A'-boroPro. These polypeptide boronic acids are generally stable and can be administered by any standard procedure to act as a substrate for DP-IV and then as a source of a potent DP-IV inhibitor. The advantages of such molecules is that inhibitor is released only in the vicinity of active DP-IV. These polypeptide boronic acids can be made by the method of mixed anhydride coupling by one of ordinary skill in the art, e.g., Mattason (*Organometallics* 3:1284, 1984).

Assays for DP-IV Inhibition

The following are examples of systems by which the inhibitory activity of the above described inhibitory compounds can be tested on DP-IV. As an example H-Ala-boroPro though not a compound in accordance with the present invention is described as being used to test each of these systems.

Inhibitory compounds can be tested by simply substituting them for H-Ala-boroPro.

DP-IV is purified from pig kidney cortex by the method of Barth et al. (*Acta Biol. Med. Germ.* 32:157, 1974) and Wolf et al. (*Acta Biol. Med. Germ.* 37:409, 1978) and from human placenta by the method of Puschel et al. (*Eur. J. Biochem.* 126:359, 1982). H-Ala-boroPro inhibits both enzymes with a K_i in the nanomolar range.

Human Peripheral blood Mononuclear Cells

H-Ala-boroPro was tested for its influence on PHA-induced proliferation of human peripheral blood

mononuclear cells. Human peripheral blood mononuclear cells were obtained from healthy human donors by Ficoll-Hypaque density gradient centrifugation. The cells are washed three times in RPMI 1640 medium and resuspended to a concentration of a 1 x 10^6 in RPMI. 10% human serum was used as necessary.

The proliferative response of lymphocytes was measured using 3H-Thymidine incorporation. 5 x 10^3 MNC cells (Ford in *Handbook of Experimental Immunology*, Weir, ed., Blackwell Scientific Publications, Oxford, 1978) were distributed into wells of round-bottom microtiter plates and incubated in the presence or absence of various dilutions of antigen, mitogen, lymphokine or other agent of interest. Cells were cultured in an atmosphere of 5% CO_2 in air for 72 hours after which ^{3}H-Thymidine (0.5 μC1/well; 2.0 Ci/mM, New England Nuclear) was added 6 hours before termination of culture. The cells were harvested with a multiple automatic harvester, and ^{3}H-thymidine incorporation assessed by liquid scintillation counting. ^{3}H thymidine incorporation was determined relative to control values in the absence of inhibitor. Inhibitor was added to give a final concentration of 1 x 10^{-4}M, but lower concentrations can be used.

HIV gene replication

We examined the effect of H-Ala-boroPro on HIV-1 replication *in vitro*. The rational for these experiments comes from the reported connection between T-cell activation, IL-2 production, and HIV replication and expression of HIV proteins. For example, inductive [illegible] include mitogens [illegible] NF-κB, all of which have been shown to be associated with induction of IL-2 production, T-cell activation, or both.

Cell lines used in the present studies include A3.5 cells (a monocyte cell line which is CD4+, HLA-DR+, and CD3-) and peripheral blood mononuclear cells (PBMC). The A3.5 cells grow continuously in culture without exogenous growth factors. PBMC cells require IL-2 for propagation *in vitro*. Cells were infected with HIV-1-IIIB at a multiplicity of infection (moi) of 5×10^{-4} tissue culture infectious dose 50 (TCID50)/cell for both the A3.5 cells and the PMBC cells. Dilutions of inhibitor were made in RPMI-1640 and subsequently passed through a 0.22 um filter. At the start of each experiment, 1×10^6 cells/well, in 24-well plates, were infected with HIV-1-IIIB at the moi indicated above. Inhibitor was added simultaneously at the appropriate dilutions. All cultures were maintained at 5% CO_2 and 37°C in RPMI-1640 supplemented with penicillin, streptomycin, L-glutamine, hepes buffer, and 20% heat-inactivated fetal calf serum. Cell counts and viability were determined by trypan blue exclusion. Culture supernatants were harvested and assayed for HIV-1 p24 antigen by ELISA (NEN-DuPont, Boston, MA). Fresh media and inhibitor were added on each day. For PBMC cultures, cells were collected from HIV-1 seronegative donors and stimulated with PHA-P (Difco, Detroit, MI; 10 μg/ml) and 10% IL-2 (Electronnucleonics, Silver Spring, MD) 3 days prior to infection with HIV-1. PBMC cultures for all experiments included uninfected and infected cells without inhibitor, uninfected cells with inhibitor at the various concentrations, and infected cells in the presence of 1 μm zidovudine (azidothymidine, AZT).

With A3.5 H-Ala-boroPro suppresses HIV below

[illegible] with the PBMC cells. Thus, the inhibitors have an anti-HIV effect. Cell viability assays show that

these inhibitors are not cytotoxic even at relatively high concentration (10^{-3}M for A3.5 cells).

Determination of DP-IV Activities in Biological Samples

The ability to determine DP-IV activities associated with cells and tissues is highly desirable. For example, it will permit correlations to be made between level of inhibition of DP-IV and the magnitude of the observed biological affect, e.g., on cell proliferation, and IL-2 production. Such correlation is helpful in establishing whether or not the biological effect is due to inhibition of DP-IV. We have found that such determinations can be reproducibly and reliably made using the readily available chromogenic substrates for DP-IV: X-Pro-p-nitroanilides and X-Pro-7-amino-4-trifluoromethyl coumarins (AFC). The AFC substrates are fluorescent and thus provide greater sensitivity. DP-IV activity is measured as release of p-nitroanilide spectrophotometrically at 410 nM, or using X-Pro-AFC derivatives and measuring fluorescence at 505 nM. Reduction in activity in the presence of inhibitor provides an easy test for inhibitory activity.

Effect of Inhibitor Stereochemistry on DP-IV Inhibition

Experiments described below demonstrate that Ala-boroPro and Pro-boroPro are potent inhibitors of DP-IV with K_i values in the nanomolar range. In addition, the L,L form of Pro-boroPro is shown to be a far more potent inhibitor of DP-IV than the L,D form of Pro-boroPro.

The activity of DP-IV, isolated from porcine kidneys by the method of Wolf et al. (*ACTA Bio. Mes. Ger.* 37:409, 1972), was measured using Ala-Pro-*p*-nitroanilide [illegible] containing 50 μmol

[illegible]

milliunits of DP-IV, and 2% (vol/vol) dimethylformamide in a total volume of 1.0 ml. The reaction was initiated

by the addition of enzyme and reaction rates were measured at 25°C.

The rates of DP-IV-catalyzed hydrolysis of Ala-Pro-*p*-nitroanilide were determined at 3 to 5 different concentration of Ala-boroPro Pro-boroPro, boroPro and *N*-Boc-Ala-boroPro. In some cases, the initial reactions rates were not linear. The rates became linear after 10 min; this linear portion can be duplicated by preincubating enzyme with inhibitor for 10 min before adding substrate. Table 1 presents the results of K_i measurements made over the linear range.

Table 1: Inhibition constants of some inhibitors of DP-IV

Inhibitor	K_i nM
N-Boc-Al-boroPro	>1,000,000*
BoroPro	110,000
Ala-boroPro	2
Pro-boroPro	3

*No inhibition detected.

Ala-boroPro was a potent inhibitor of DP-IV, having a K_i value of 2×10^{-9}M (Table 1). Blocking the N terminus of this inhibitor (e.g., *N*-Boc-Ala-boroPro; Table 1) abolished inhibition, demonstrating that a free, positively charged amino group is likely essential for enzyme recognition and binding. The K_i of 3×10^{-9} M for Pro-boroPro demonstrates that DP-IV tolerates an imino group in place of the amino functional group on the N

[illegible] substitution of a proline side

[illegible] that the S2 specificity subsite is not highly restrictive. Although DP-IV will accept nearly any amino acid at the N terminus, interactions between this amino

acid and the enzyme are critical for binding. This is illustrated by the 10^5-10^6 decrease in affinity on going from Ala-boroPro or Pro-boroPro to boroPro itself (Table 1).

The inhibition experiments presented in Table 1 were carried out on DP-IV isolated from pig kidneys. Pro-boroPro and Ala-boroPro inhibit DP-IV from human placenta equally well.

The Ala-boroPro and Pro-boroPro used in the experiments described above were raecemic mixtures in which the boroPro moiety was present as both the D-form and L-form while Ala and Pro were both the L-isomer.

High pressure liquid chromatography (HPLC) can be used to separate L-Pro-D-boroPro from L-Pro-L-boroPro. A 4.6 mm x 250 mm Nucleosil C18 (5μ particle) column employing a two buffer system (Buffer A is 100% H_2O with 0.1% TFA, and buffer B is 70% CH_3CN, 30% H_2O, 0.86% TFA) can be used to carry out the seperation. From 0 to 5 min 5% B and 95% A is used, and from 5 to 25 min 5% to 100% B is used. The L,L isomer comes off first at about 7 min, followed by the L,D isomer at about 10 min. NMR and mass spectra analysis were consistent with both compounds being Pro-boroPro. Rechromatography of the purified isomers indicated that the first pass on the HPLC column achieved an isomeric purity of about 99-6% for each isomer. High pressure liquid chromatography (HPLC) can similarly be used to be used to separate L-Ala-D-boroPro from L-Ala-L-boroPro or to seperate the D-boroPro form of other inhibitors from the L-boroPro form.

When L-Pro-L-boroPro and L-Pro-D-boroPro were used in a DP-IV inhibition assay, the K_i for L-Pro-L-boroPro

[illegible] isomer [illegible] much better inhibitor for DP-IV than the L,D-isomer. Further it is preferred that all of the amino acid residues of the DP-

IV inhibitors of the invention be the L-isomer rather than the D-isomer.

The inhibitory compounds can be administered in an effective amount either alone or in combination with a pharmaceutically acceptable carrier or diluent.

The above inhibitory compounds are useful for treatment of a wide variety of disease; for example, an autoimmune disease, the pathogenesis of which is dependent on T cell activity. DP-IV plays a role in such autoimmune disease and inhibition of DP-IV activity allows regulation of the progress of the disease. Such diseases include arthritis, rejection of transplanted organs, as well as SLE and AIDS. When administered to mammals (e.g., orally, topically, intramuscularly, intraperitoneally, intravenously, parenterally, nasally or by suppository), the inhibitory compounds of this invention enhance the ability of, e.g., the immune system of the mammal, to fight the disease.

Inhibitors of DP-IV can suppress IL-2 production and thus diseases in which the production of IL-2 is altered may be treated by use of these inhibitors. These inhibitors can also delay catabolism of growth hormone releasing factor, and block DP-IV activity of amoebae and microbial pathogens to allow an immune system to act more efficiently.

The inhibitory compounds or compositions can be administered alone or in combination with one another, or in combination with other therapeutic agents. The dosage level may be between 1 - 500 mg/kg/day.

isomer inhibitors can be created which mimic the structure of Ala-boroPro.

Claims

1. A purified inhibitor of the amino peptidase activity of dipeptidyl peptidase type IV (hereafter "DP-IV"), having the structure:



wherein m is an integer between 0 and 10, inclusive; A and A' are L-amino acid residues such that the A in each repeating bracketed unit can be a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A' and C, and between A' and N are peptide bonds; and each X^1 and X^2 is, independently, a hydroxyl group or a group capable of being hydrolysed to a hydroxyl group at physiological pH.

2. An inhibitor as claimed in claim 1, wherein X^1 and X^2 are hydroxyl groups.

3. An inhibitor as claimed in claim 1 or claim 2, wherein A and A' are independently proline or alanine residues.

4. An inhibitor as claimed in any of claims 1-3, wherein m is 0.

5. An inhibitor as claimed in any of claims 1-4, with the proviso that, when m is 0, A' is other than Ala.

7. An inhibitor as claimed in any of claims 1-5, wherein said inhibitor is L-Pro-L-boroPro.

8. An inhibitor as claimed in any of claims 1-7, with an isomeric purity of about 96-99%.

9. A pharmaceutical composition comprising one or more inhibitors according to any of claims 1 to 8, together with a pharmaceutical carrier or diluent.

10. A preparation comprising an inhibitor as claimed in any of claims 1-8, or a composition as claimed in claim 9, wherein said inhibitor is present with an isomeric purity of about 96-99%.

11. An inhibitor as claimed in any of claims 1-8, for use in inhibiting the enzymatic activity of DP-IV in a mammal, preferably for regulation of an immune response.

12. Use of an inhibitor as claimed in any of claims 1-8, for the manufacture of a medicament for use in inhibiting the enzymatic activity of DP-IV in a mammal, preferably for regulation of an immune response.

FIG.1



4-bromo-1-chlorobutyl boronate pinacol



4-bromo-1[(bistrimethylsilyl) amino] butyl bornonate pinacol



1-trimethylsilyl-boroProline pinacol

(IV)

boroProline-pinacol-HCL

IV

CH

Boc-Ala--boroPro-pinacol

Boc-Ala-boroPro-pinacol —4N HCl / Dioxane→ Ala-boroPro-pinacol

CLAIMS:

1. An inhibitor of the amino peptidase activity of dipeptidyl peptidase type IV (hereafter "DP-IV"), having the structure:



wherein m is an integer between 0 and 10, inclusive; A and a' are L-amino acid residues such that the A in each repeating bracketed unit can be a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A and C, and between A and N are peptide bonds; and each X^1 and X^2 is, independently, a hydroxyl group or a group capable of being hydrolysed to a hydroxyl group at physiological pH.

2. The inhibitor of Claim 1 wherein X^1 and X^2 are hydroxyl groups.

3. An inhibitor of the amino peptidase activity of dipeptidyl peptidase type IV (hereafter "DP-IV"), having the structure:



wherein m is an integer between 0 and 4, inclusive; A and A' are

unit can be a different amino acid residue; the C bonded to T is in the L-configuration; the bonds between A and N, A and C, and between A and N are peptide bonds; and T is either:

(i) 

where G is either H, F or an alkyl group containing 1 to 20 carbon atoms and optional heteroatoms which can be N, S or O; or

(ii) 

where each J, independently, is O-alkyl, N-alkyl, or alkyl, each alkyl including 1 to 20 carbon atoms and optional heteroatoms which can be N, S or O.

4. The inhibitor of Claim 3, wherein T is a phosphonate group.

5. The inhibitor of Claim 3, wherein T is a trifluoroalkyl ketone group.

6. The inhibitor of Claims 1 or 3, wherein A and A' are independently proline or alanine residues.

7. The inhibitor of Claims 1 or 3, wherein m is O.

8. The inhibitor of Claims 1 or 3, with the proviso that when m is O, A' is other than Ala.

9. The inhibitor of Claims 1 or 3, wherein said inhibitor is

L-Pro-L-boroPro.

11. A pharmaceutical composition comprising one or more inhibitors according to any of Claims 1 to 10, together with a pharmaceutical carrier or diluent.

12. A preparation comprising the inhibitor of Claims 1 or 3, or a composition according to Claim 11, wherein said inhibitor is present with isomeric purity of at least 96%, preferably 96 to 99%.

13. A compound of the structure defined in any of Claims 1 to 10, for use in inhibiting the enzymatic activity of DP-IV in a mammal, preferably for regulation of the immune response.

14. Use of a compound of the structure defined in any of Claims 1 to 10, for the manufacture of a medicament for use in inhibiting the enzymatic activity of DP-IV in a mammal, preferably for regulation of the immune response.

15. Use according to Claim 14, wherein said compound is present in said medicament with isomeric purity of at least 96%, preferably 96 to 99%.